Levamisole hydrochloride (DrugBank: Levamisole)
3 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
60 | 再生不良性貧血 | 2 |
61 | 自己免疫性溶血性貧血 | 0 |
62 | 発作性夜間ヘモグロビン尿症 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03218657 (ClinicalTrials.gov) | January 1, 2018 | 16/6/2017 | Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole | A Prospective, Randomized, Controlled Clinical Study of Non Transfusion Dependent Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole Hydrochloride | Aplastic Anemia | Drug: levamisole hydrochloride;Drug: Androgens;Drug: Cyclosporins | Shengyun Lin | NULL | Recruiting | 18 Years | 70 Years | All | 248 | N/A | China |
2 | ChiCTR-IOR-17011653 | 2017-07-01 | 2017-06-14 | A prospective, randomized, controlled clinical study of non transfusion dependent non severe aplastic anemia treated with cyclosporine, androgen and levamisole hydrochloride | A prospective, randomized, controlled clinical study of non transfusion dependent non severe aplastic anemia treated with cyclosporine, androgen and levamisole hydrochloride | Aplastic anemia | SA group:none;LSA group:levamisole hydrochloride; | The First affiliated Hospital of Zhejiang Chinese Medical University | NULL | Pending | 18 | 70 | Both | SA group:124;LSA group:124; | China |